IP Verse

Method Of Assessing Risk Of Pml - EP3575792

The patent EP3575792 was granted to Biogen MA on Nov 30, 2022. The application was originally filed on May 31, 2012 under application number EP19169482A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3575792

BIOGEN MA
Application Number
EP19169482A
Filing Date
May 31, 2012
Status
Granted And Under Opposition
Oct 28, 2022
Grant Date
Nov 30, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SANDOZAug 30, 2023WICHMANNADMISSIBLE
POLPHARMA BIOLOGICSDec 1, 2022WICHMANNADMISSIBLE

Patent Citations (17) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS19840615085-
DESCRIPTIONUS20100614918-
DESCRIPTIONWO2011US20832-
DESCRIPTIONUS3817837
DESCRIPTIONUS3850752
DESCRIPTIONUS3939350
DESCRIPTIONUS3996345
DESCRIPTIONUS4275149
DESCRIPTIONUS4277437
DESCRIPTIONUS4366241
DESCRIPTIONUS4833092
DESCRIPTIONUS6258562
DESCRIPTIONWO0155112
EXAMINATIONWO2011085369
OPPOSITIONWO2011085369
OPPOSITIONWO2014193804
OTHERWO2011085369

Non-Patent Literature (NPL) Citations (53) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- Amer. J. Physiol. - Heart and Circulatory Physiology, (19950000), vol. 268, pages 37 - 42-
DESCRIPTION- Ann. Neurol., (20100000), vol. 68, pages 295 - 303-
DESCRIPTION- Ann. Neurol., (20110000), vol. 70, pages 742 - 750-
DESCRIPTION- Arthritis & Rheumatism, (19940000), vol. 37, page 295-
DESCRIPTION- Arthritis & Rheumatism, (19960000), vol. 39, page 284-
DESCRIPTION- DEVLIN et al., Science, (19900000), vol. 249, pages 400 - 406-
DESCRIPTION- J. Invest. Med., (19960000), vol. 44, page 235A-
DESCRIPTION- PICCINNI et al., "Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological immunomodulating agents", Eur. J. Clin. Pharmacol., (20100000), vol. 66, pages 199 - 206, XP019778034-
DESCRIPTION- POLMAN et al., N. Engl. J. Med., (20060000), vol. 354, pages 899 - 910-
DESCRIPTION- SCOTT; SMITH, Science, (19900000), vol. 249, pages 386 - 390-
DESCRIPTION- TYLER, Ann. Neurol., (20100000), vol. 68, pages 271 - 274-
EXAMINATION- WRIGHT P F ET AL, "Standardisation and validation of enzyme-linked immunosorbent assay techniques for the detection of antibody in infectious disease diagnosis.", REVUE SCIENTIFIQUE ET TECHNIQUE (INTERNATIONAL OFFICE OF EPIZOOTICS) JUN 1993, (199306), vol. 12, no. 2, ISSN 0253-1933, pages 435 - 450, XP008036954-
EXAMINATION- HOU JEAN ET AL, "JC virus can infect human immune and nervous system progenitor cells: implications for pathogenesis.", ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2006, (2006), vol. 577, doi:10.1007/0-387-32957-9_19, ISSN 0065-2598, pages 266 - 273, XP093025785
OPPOSITION- Allergy, "Yman Lars", Allergy, David Wild, The Immunoassay Handbook Third Edition, Elsevier Ltd., (20050101), pages 695 - 699, ISBN 0-08-044526-8, XP093130359-
OPPOSITION- Anonymous, "StratifyJCV DxSelect", Focus diagnostics, (20151124), pages 1 - 15, XP093130536-
OPPOSITION- Bozic C, Subramanyam M, Paes D, Richman S, Plavina T, Zhang A, Ticho B, "JCV Epidemiology in MS (JEMS): prevalence of anti-JC virus antibodies in multiple sclerosis patients", Poster P466 on 22nd Annual Meeting of the European Neurological Society, (20120601), XP093176402-
OPPOSITION- Chris Davies, "Concepts", Chris Davies, David Wild, The Immunoassay Handbook Third Edition, Elsevier Ltd., (20050101), pages 103 - 103, ISBN 0-08-044526-8, XP093130332-
OPPOSITION- Davies Chris, "Introduction to Immunoassay Principles", Davies Chris, David Wild, The Immunoassay Handbook Third Edition, Elsevier Ltd., (20050101), pages 3 - 25, ISBN 0-08-044526-8, XP093130311-
OPPOSITION- Ema, "Guideline on bioanalytical method validation", EMEA/CHMP/EWP/192217/2009 Rev. 1 Corr. 2, (20110721), pages 1 - 23, XP093176403-
OPPOSITION- Ema, "Tysabri 300 mg concentrate for solution for infusion ", ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS, (20230124), pages 1 - 79, ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS, URL: https://www.ema.europa.eu/en/documents/product-information/tysabri-epar-product- information_en.pdf, XP093158211-
OPPOSITION- Ho P-R, "Supplementary appendix to Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies", The Lancet Neurology, (20170929), pages 1 - 8, XP093176401-
OPPOSITION- Lee P , Plavina T, Castro A, Berman M, Jaiswal D, Rivas S, Schlain B, Subramanyam M, "An enhanced ELISA for detection of anti-JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification", 22nd Annual Meeting of the European Neurological Society, (20120101), pages 1 - 1, XP093130496-
OPPOSITION- Liddell Eryl, "Antibodies", Liddell Eryl, David Wild, The Immunoassay Handbook Third Edition, Elsevier Ltd, (20050101), pages 144 - 145, ISBN 0-08-044526-8, XP093130345-
OPPOSITION- Rhys John, Carole A. Spencer, Nic Christofides , David Wild, "Thyroid", Rhys John, Carole A. Spencer, Nic Christofides , David Wild, David Wild, The Immunoassay Handbook Third Edition, Elsevier Ltd., (20050101), pages 1 - 4, ISBN 0-08-044526-8, XP093130356-
OPPOSITION- Warnhe Clemens, Menge Til, Hartung Hans-Peter, Racke Michael K, Cravens Petra D, Bennett Jeffrey L, Frohman Euiot M, Greenberg Benjamin M, Zamvil Scott S, Gold Ralf, Hemmer Bernhard, Kieseier Bernd C, Stiive Olaf, "Natalizumab and Progressive Multifocal Leukoencephalopathy What Are the Causal Factors and Can It Be Avoided?", Arch Neural, (20100801), vol. 67, no. 8, pages 923 - 930, XP093130267-
OPPOSITION- Leonid Gorelik, Michaela Lerner, Sarah Bixler, Mary Crossman, Brian Schlain, Kenneth Simon, Amy Pace, Anne Cheung, Ling Ling Chen, Melissa Berman, Fairuz Zein, Ewa Wilson, Ted Yednock, Alfred Sandrock, Susan E. Goelz, Meena Subramanyam, "Anti-JC virus antibodies: Implications for PML Risk Stratification", Annals of Neurology, (20100901), vol. 68, no. 3, doi:10.1002/ana.22128, ISSN 03645134, pages 295 - 303, XP055136721
OPPOSITION- Kenneth L. Tyler, "Progressive multifocal leukoencephalopathy: Can we reduce risk in patients receiving biological immunomodulatory therapies?", Annals of Neurology, Boston , US , (20100831), vol. 68, no. 3, doi:10.1002/ana.22185, ISSN 0364-5134, pages 271 - 274, XP071639310
OPPOSITION- Tatiana Plavina, Meena Subramanyam, Gary Bloomgren, Sandra Richman, Amy Pace, Sophia Lee, Brian Schlain, Denise Campagnolo, Shibeshih Belachew, Barry Ticho, "Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy : Anti-JCV Antibody and PML Risk", Annals of Neurology, Boston , US , (20141201), vol. 76, no. 6, doi:10.1002/ana.24286, ISSN 0364-5134, pages 802 - 812, XP055538158
OPPOSITION- Khalili Kamel, Gordon Jennifer, White Martyn K, "The Polyomavirus, J CV, and Its Involvement in Human Disease", Khalili Kamel, Gordon Jennifer, White Martyn K, Nasimul Ahsan, Polyomaviruses and human diseases, Springer , (20060101), pages 274 - 287, doi:10.1007/0-387-32957-9_20, ISBN 978-0-387-29233-5, XP093130488
OPPOSITION- Viscidi Raphael P., Clayman Barbara, "Serological Cross Reactivity between Polyomavirus Capsids", Viscidi Raphael P., Clayman Barbara, Ahsan Nasimul, Polyomaviruses and Human Diseases, New York, NY, Springer New York, (20060101), vol. 577, pages 73 - 84, doi:10.1007/0-387-32957-9_5, ISSN 0065-2598, ISBN 978-0-387-32957-4, XP093130481
OPPOSITION- Peter Lee, Plavina Tatiana, Castro Albert, Berman Melissa, Jaiswal Dipeshkumar, Rivas Suzanne, Schlain Brian, Subramanyam Meena, "A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification", Journal of clinical virology, NL , (20130601), vol. 57, no. 2, doi:10.1016/j.jcv.2013.02.002, ISSN 1386-6532, pages 141 - 146, XP055555106
OPPOSITION- Kannel William B, Wilson Peter W.F, Nam Byung-H.O, D’agostino Ralph B, "Risk stratification of obesity as a coronary risk factor", American Journal of Cardiology, US , (20021001), vol. 90, no. 7, doi:10.1016/S0002-9149(02)02592-4, ISSN 0002-9149, pages 697 - 701, XP093130295
OPPOSITION- Cinque Paola, Koralnik Igor J., Gerevini Simonetta, Miro Jose M., Price Richard W., "Progressive Multifocal Leukoencephalopathy Complicating HIV-1 Infection", The Lancet Infectious Diseases, AMSTERDAM, NL , (20091001), vol. 9, no. 10, doi:10.1016/S1473-3099(09)70226-9, ISSN 1473-3099, pages 625 - 636, XP093130255
OPPOSITION- Tan Chen S, Koralnik Igor J, "Beyond progressive multifocal leukoencephalopathy: expanded pathogenesis of JC virus infection in the central nervous system", The Lancet Neurology, AMSTERDAM, NL, (20100401), vol. 9, no. 4, doi:10.1016/S1474-4422(10)70040-5, ISSN 1474-4422, pages 425 - 437, XP093130473
OPPOSITION- Ho Pei-Ran; Koendgen Harold; Campbell Nolan; Haddock Bill; Richman Sandra; Chang Ih, "Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies", The Lancet Neurology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (19000101), vol. 16, no. 11, doi:10.1016/S1474-4422(17)30282-X, ISSN 1474-4422, pages 925 - 933, XP085239965
OPPOSITION- Eugene O Major, "Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned", The Lancet Neurology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20180501), vol. 17, no. 5, doi:10.1016/S1474-4422(18)30040-1, ISSN 1474-4422, pages 467 - 480, XP093158213
OPPOSITION- Gary Bloomgren, Sandra Richman, Christophe Hotermans, Meena Subramanyam, Susan Goelz, Amy Natarajan, Sophia Lee, Tatiana Plavina, James V. Scanlon, Alfred Sandrock, Carmen Bozic, "Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy", New England Journal of Medicine, (20120517), vol. 366, no. 20, doi:10.1056/NEJMoa1107829, ISSN 0028-4793, pages 1870 - 1880, XP055049527
OPPOSITION- Adrian Egli, Laura Infanti, Alexis Dumoulin, Andreas Buser, Jacqueline Samaridis, Christine Stebler, Rainer Gosert, Hans h. Hirsch, "Prevalence of Polyomavirus BK and JC Infection and Replication in 400 Healthy Blood Donors", Journal of Infectious Diseases, University of Chicago Press, US, US , (20090315), vol. 199, no. 6, doi:10.1086/597126, ISSN 0022-1899, pages 837 - 846, XP055491320
OPPOSITION- CARTER J J, ET AL, "Lack of serologic evidence for prevalent simian virus 40 infection in humans", JNCI CANCER SPECTRUM, OXFORD UNIVERSITY PRESS, OXFORD, GB, GB , (20031015), vol. 95, no. 20, doi:10.1093/jnci/djg074, ISSN 1475-4029, pages 1522 - 1530, XP002564467
OPPOSITION- C. Bozic; M. Subramanyam; S. Richman; T. Plavina; A. Zhang; B. Ticho, "Anti‐JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial", EUROPEAN JOURNAL OF NEUROLOGY, RAPID SCIENCE PUBLISHERS., GB, GB , (20131130), vol. 21, no. 2, doi:10.1111/ene.12304, ISSN 1351-5101, pages 299 - 304, XP072030085
OPPOSITION- C Mcguigan, "Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group", JOURNAL OF NEUROLOGY NEUROSURGERY & PSYCHIATRY., BMJ Publishing Group, GB, GB , (20160201), vol. 87, no. 2, doi:10.1136/jnnp-2015-311100, ISSN 0022-3050, pages 117 - 125+Sup, XP093158226
OPPOSITION- Hunt David, Giovannoni Gavin, "Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring", Practical neurology, London, UK , (20120201), vol. 12, no. 1, doi:10.1136/practneurol-2011-000092, ISSN 1474-7758, pages 25 - 35, XP093130521
OPPOSITION- Fox Robert J, Richard A. Rudick, "Risk stratification and patient counseling for natalizumab in multiple sclerosis", Neurology, (20120207), vol. 78, no. 6, doi:10.1212/WNL.0b013e318245d2d0, pages 436 - 437, XP093130513
OPPOSITION- AK Trampe et al., "Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.", Neurology, (20120509), vol. 78, doi:10.1212/WNL.0b013e3182583022, XP055037291
OPPOSITION- Jaime M. Kean, "Seroepidemiology of Human Polyomaviruses", PLOS PATHOGENS, PUBLIC LIBRARY OF SCIENCE, US, US , (20090327), vol. 5, no. 3, doi:10.1371/journal.ppat.1000363, ISSN 1553-7374, page e1000363, XP093158216
OPPOSITION- Berger Joseph R., Houff Sidney A., Major Eugene O., "Monoclonal antibodies and progressive multifocal leukoencephalopathy", mAbs, US , (20091101), vol. 1, no. 6, doi:10.4161/mabs.1.6.9884, ISSN 1942-0862, pages 583 - 589, XP093130366
OTHER- Jean Hou, Pankaj Seth And Eugene O. Major, "Chapter 19 - JC Virus Can Infect Human Immune and Nervous System Progenitor Cells: Implications for Pathogenesis", Jean Hou, Pankaj Seth And Eugene O. Major, Nasimul Ahsan, ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, Volume 577- Polyomaviruses and Human Diseases, Springer Science+Business Media, (20060000), pages 3pp, xvii-xxiii, 266 - 273, XP055742402-
OTHER- WRIGHT P F; ET AL, "STANDARDISATION AND VALIDATION OF ENZYME-LINKED IMMUNOSORBENT ASSAY TECHNIQUES FOR THE DETECTION OF ANTIBODY IN INFECTIOUS DISEASE DIAGNOSIS", Rev. sci. tech. Off. int. Epiz., (19930000), vol. 12, no. 2, pages 435 - 450, XP008036954-
SEARCH- SANDROCK ALFRED ET AL, "Risk Stratification for Progressive Multifocal Leukoencephalopathy (PML) in MS Patients: Role of Prior Immunosuppressant Use, Natalizumab-Treatment Duration, and Anti-JCV Antibody Status", NEUROLOGY, & 63RD ANNUAL MEETING OF THE AMERICAN-ACADEMY-OF-NEUROLOGY; HONOLULU, HI, USA; APRIL 09 -16, 2011, (201103), vol. 76, no. 9, Suppl. 4, ISSN 0028-3878, page A248, XP055189963 [X] 4-15 * para "introduction" ; Fig 3 ; col 4, para "Conclusions" * [A] 1-3-
SEARCH- SUBRAMANYAM MEENA ET AL, "Anti-JCV Antibodies Are Consistently Detected Prior to and after PML Diagnosis in Natalizumab-Treated MS Patients", NEUROLOGY, & 63RD ANNUAL MEETING OF THE AMERICAN-ACADEMY-OF-NEUROLOGY; HONOLULU, HI, USA; APRIL 09 -16, 2011, (201103), vol. 76, no. 9, Suppl. 4, ISSN 0028-3878, pages A636 - A637, XP008176353 [X] 4-15 * abstract * [A] 1-3-
SEARCH- WARNKE CLEMENS ET AL, "Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?", ARCHIVES OF NEUROLOGY,, (20100801), vol. 67, no. 8, doi:10.1001/ARCHNEUROL.2010.161, pages 923 - 930, XP009146630 [X] 4-15 * abstract ; pg 6, col 1, para 4 * [A] 1-3
SEARCH- LEONID GORELIK ET AL, "Anti-JC virus antibodies: Implications for PML Risk Stratification", ANNALS OF NEUROLOGY, (20100824), vol. 68, no. 3, doi:10.1002/ana.22128, ISSN 0364-5134, pages 295 - 303, XP055136721 [X] 4-15 * pg 296, col 1, para 1-2 * [A] 1-3
SEARCH[ ] - A. Q. REUWER ET AL, "The clinical utility of JC virus antibody index measurements in the context of progressive multifocal leukoencephalopathy", ACTA NEUROLOGICA SCANDINAVICA., DK, (20171101), vol. 136, doi:10.1111/ane.12840, ISSN 0001-6314, pages 37 - 44, XP055628651 [ ] * abstract ; pg 41, col 2, para 1 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents